Key result
Tailoring antihypertensive therapy to comorbidities remains essential as ARNIs and nonsteroidal MRAs gain clinical significance.
Why the study?
Isolated hypertension is uncommon and often involves comorbid diseases requiring specific regimentation, warranting a review of current evidence and misconceptions regarding antihypertensive drug classes across common comorbidities.
This review highlights the importance of tailoring antihypertensive therapy to specific comorbidities, noting the emerging role of newer agents like ARNIs and nonsteroidal MRAs.
PURPOSE OF REVIEW: In this article, we review the most current evidence for initiation and maintenance of various antihypertension (HTN) drug classes, including other misconceptions with respect to common comorbidities in patients with HTN. RECENT FINDINGS: Although the currently available anti-HTN agents have broad applicability in treating HTN, additional agents, such as angiotensin receptor-neprilysin inhibitors and novel nonsteroidal mineralocorticoid antagonists, have recently gained clinical significance. In addition, there have been some anecdotal concerns regarding the adverse effects, indications, and risks of COVID-19 infection/mortality when using certain anti-HTN agents. SUMMARY: Current guidelines currently address the treatment of primary HTN. However, isolated HTN is uncommon and often involves comorbid diseases that require specific regimentation. Several experimental medications are currently in late-stage trials showing potential superiority over current drugs that are available in the market.
No takes yet. Share an insight, caveat, or question.
Mendoza et al. (2021) conducted a review in Hypertension with comorbidities. Antihypertension drug classes was evaluated. Tailoring antihypertensive therapy to specific comorbidities is necessary, with newer agents like ARNIs and nonsteroidal MRAs gaining clinical significance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: